CXCL12 and glioblastoma: Nanoparticles have also been used to target the CXCL12/CXCR4 signaling in mouse and human GBM in vitro and vivo, resulting in a decrease in GBM proliferation associated with a decreased infiltration of MDSCs and an increase in immunogenic cell death [100].